RAS-driven cancers | Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

97,130 results for “RAS-driven cancers”

Trials

View all 78111 →

Rechallenge With Panitumumab Driven by RAS Dynamic of Resistance

32 participants · First posted Jul 24, 2017

Studying Pathways of Resistance in KRAS-driven Cancers

58 participants · First posted Mar 9, 2022

Active, not recruiting

Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial

199 participants · First posted Sep 26, 2022

Drugs

View all 2628 →

C-4

selective monovalent direct degrader(CRAF, RAS-driven cancer)

RAS-F3

Organizations

View all 553 →

Erasca

United States

ASSO DE RECHERCHE CANCERS GYNECOLOGIQUES

France

Revolution Medicines, Inc.

United States

News

View all 15838 →

Dana-Farber Launches Center for RAS Therapeutics to Combat Drug Resistance

Vividion Therapeutics Initiates Phase I Trial of Novel RAS-PI3Kα Inhibitor for Advanced Solid Tumors

Revolution Medicines' RMC-6236: A Novel Pan-RAS(ON) Inhibitor Shows Promise in 'Undruggable' Tumors

Page 1 of 9713